A new case report describes an 8-year-old girl with severe atopic dermatitis who started treatment with dupilumab. Three months later, she developed vitiligo, a condition that causes loss of skin color in patches. The report also notes that her itching improved. The authors also reviewed other published cases and say a possible time-related link between dupilumab and vitiligo cannot be ruled out. However, this is a single case, and a case report cannot prove that dupilumab caused the vitiligo. Many other factors could be involved, and the report does not provide details on the girl's other treatments or her medical history. The authors stress that causality cannot be established from the available evidence. For patients using dupilumab, this is a reminder that new skin changes should be discussed with a doctor. The findings do not change the overall safety profile of dupilumab, which remains an important treatment for severe eczema. More research is needed to understand if there is any real connection.
Dupilumab for Severe Pediatric Atopic Dermatitis Followed by Vitiligo Three Months LaterChild Develops Vitiligo After Starting Dupilumab
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This publication is a case report and literature review examining the development of vitiligo in an 8-year-11-month-old girl with severe atopic dermatitis who was treated with dupilumab. The report describes vitiligo onset three months after dupilumab initiation. The authors also list prior topical and antihistamine therapies including hydrocortisone butyrate, pimecrolimus, tacrolimus, cetirizine, and loratadine, though the comparator is not reported.
The primary outcome was the development of vitiligo, with pruritus noted as a secondary outcome. No effect size, p-value, or confidence interval was reported. Follow-up duration and setting were not reported. The reported adverse event was vitiligo; serious adverse events, discontinuations, and tolerability were not reported.
The authors explicitly state that causality cannot be established from the currently available evidence. They describe a possible temporal association between dupilumab exposure and vitiligo development. The case report format and single-patient sample preclude any inference about incidence, risk, or mechanism.
Practice relevance was not reported. Clinicians should interpret this as a single case observation that cannot establish a causal relationship between dupilumab and vitiligo. No changes to monitoring or prescribing are supported by this level of evidence.
How this fits prior evidence
This case report and literature review adds a single pediatric observation to the broader dupilumab safety literature, but it does not confirm or extend prior coverage on biologics for chronic rhinosinusitis with nasal polyps, where biologics provide effective and long-lasting disease control. It also does not address the prior note that IRF4 evidence for psoriasis is limited to a single 2025 mouse model. The report is consistent with prior coverage emphasizing that single cases or limited models cannot establish causality. No prior coverage item addressed dupilumab and vitiligo specifically.
Common questions
Is dupilumab safe for children with eczema?
Dupilumab is approved for some children with severe eczema, but this case report describes one girl who developed vitiligo three months after starting it. The report does not prove the drug caused the vitiligo. Safety should be discussed with your child's doctor, who can weigh benefits and risks.
Can dupilumab cause vitiligo?
This case report describes a possible time-related link between dupilumab and vitiligo in one child, but causality cannot be established from the available evidence. More research is needed to know if dupilumab can actually cause vitiligo. Talk to your doctor if you notice new skin changes.
What is vitiligo?
Vitiligo is a condition where patches of skin lose their color. In this case report, an 8-year-old girl with severe atopic dermatitis developed vitiligo three months after starting dupilumab. The report does not say whether the vitiligo improved or worsened over time.
Should I stop dupilumab if I see skin color changes?
This case report cannot tell you what to do. It only describes one child who developed vitiligo after starting dupilumab. If you notice new skin changes while taking dupilumab, talk to your doctor. Do not stop or change your treatment without medical advice.
More on Atopic Dermatitis
View Original Abstract ↓
First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer
Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival
Related in Oncology
From Other Specialties
